Literature DB >> 22654539

Giant cell reparative granuloma of the proximal phalanx: A case report and literature review.

A Perkins1, A Izadpanah, H Sinno, C Bernard, Hb Williams.   

Abstract

The present article is a case report of a 16-year-old boy who presented with a benign bony tumour, which on histological analysis suggested giant cell reparative granuloma (GCRG), but was not corroborate by blood tests. The implications of this type of tumour and the correct diagnostic requirements were investigated. The correct identification of GCRG from other giant cell-containing tumours is important because the treatment modalities for these tumours significantly differ from one another. In most cases, histological findings are sufficient to identify the tumours. In most GCRG cases, curettage is usually a curative treatment option. However, due to high recurrence rates of GCRGs, close follow-up of these patients is warranted. Also, due to osteoclastic activity of the giant cells in GCRGs, the use of drugs such as calcitonin or bisphosphonates, which inhibit osteoclast differentiation and activation, may have an important influence on future treatments or in reducing the recurrence rate of these tumours.

Entities:  

Keywords:  Bony tumour; Giant cell granuloma; Phalanx

Year:  2011        PMID: 22654539      PMCID: PMC3328113     

Source DB:  PubMed          Journal:  Can J Plast Surg        ISSN: 1195-2199


  18 in total

1.  Giant cell reparative granuloma of the small bones of the hands and feet: a report of three cases.

Authors:  F A Forouhar; N P Phelan; D C Benton
Journal:  Ann Clin Lab Sci       Date:  2000-07       Impact factor: 1.256

2.  Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-oseous) dysplasia of the jawbones.

Authors:  H L JAFFE
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1953-01

3.  Aggressive giant cell reparative granuloma of the metacarpal: a case report.

Authors:  E Giza; P J Stern; H Cualing
Journal:  J Hand Surg Am       Date:  1997-07       Impact factor: 2.230

4.  Multicentric giant cell reparative granuloma of the small bones of the hand. A case report and review of the literature.

Authors:  P M Caskey; M D Wolf; R E Fechner
Journal:  Clin Orthop Relat Res       Date:  1985-03       Impact factor: 4.176

5.  Giant cell reparative granuloma of the hand.

Authors:  S M Wenner; K Johnson
Journal:  J Hand Surg Am       Date:  1987-11       Impact factor: 2.230

6.  Giant-cell reparative granuloma of the hand and foot bones.

Authors:  V Ratner; H D Dorfman
Journal:  Clin Orthop Relat Res       Date:  1990-11       Impact factor: 4.176

7.  Giant cell reparative granuloma of the temporal bone treated with calcitonin.

Authors:  Melanie A Souter; Philip A Bird; Jim P Worthington
Journal:  Otol Neurotol       Date:  2006-10       Impact factor: 2.311

8.  The central giant cell reparative granuloma of the jaws. An analysis of 38 cases.

Authors:  C A Waldron; W G Shafer
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

9.  Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone.

Authors:  H R Dürr; M Maier; V Jansson; A Baur; H J Refior
Journal:  Eur J Surg Oncol       Date:  1999-12       Impact factor: 4.424

Review 10.  Giant cell reparative granuloma of the phalanx of the hand with aggressive radiographic features.

Authors:  F Bertoni; R Biscaglia; P Bacchini
Journal:  Skeletal Radiol       Date:  1998-10       Impact factor: 2.199

View more
  2 in total

Review 1.  Radiological features of central giant cell granuloma: comparative study of 7 cases and literature review.

Authors:  Samip Shrestha; Jia Zhang; Jun Yan; Xiaomin Zeng; Xiaoyong Peng; Bo He
Journal:  Dentomaxillofac Radiol       Date:  2021-04-21       Impact factor: 3.525

2.  Denosumab Treatment for Aggressive Multiple Recurrent Familial Central Giant-cell Granulomas.

Authors:  Eelis Rytkönen; Vuokko Ottavainen; Aleksi Rytkönen; Sanna Uusitalo; Petri Lehenkari; George K Sándor
Journal:  Ann Maxillofac Surg       Date:  2018 Jul-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.